• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
【24h】

18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.

机译：18F-胆碱，11C-胆碱和11C-乙酸酯PET / CT：对前列腺癌患者成像的比较分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer (PCA) is the second most common tumour in men worldwide. Whereas prostate specific antigen (PSA) is an established biochemical marker, the optimal imaging method for all clinical scenarios has not yet been found. With the rising number of PET centres there is an increasing availability and use of (18)F-/(11)C-choline or (11)C-acetate for staging of PCA. However, to date no final conclusion has been reached as to whether acetate or choline tracers should be preferred. In this review we provide an overview of the performance of choline and acetate PET for staging the primary and recurrent disease and lymph nodes in PCA, based on the literature of the last 10 years. Although predominantly choline has been used rather than acetate, both tracers performed in a similar manner in published studies. Choline as well as acetate have insufficient diagnostic accuracy for the staging of the primary tumour, due to a minimum detectable tumour size of 5 mm and inability to differentiate PCA from benign prostate hyperplasia, chronic prostatitis and high-grade intraepithelial neoplasia. Regarding lymph node staging, choline tracers have demonstrated a high specificity. Unfortunately, the sensitivity is only moderate. For staging recurrent disease, sensitivity depends on the level of serum PSA (PSA should be >2 ng/ml). This applies to both choline and acetate. However, despite these limitations, a significant number of patients with recurrent disease can benefit from PET imaging by a change in treatment planning.
机译：前列腺癌（PCA）是全世界男性中第二常见的肿瘤。前列腺特异性抗原（PSA）是已建立的生化标志物，但尚未找到针对所有临床情况的最佳成像方法。随着PET中心数量的增加，用于PCA分期的（18）F-/（11）C-胆碱或（11）C-乙酸盐的可用性和使用量都在增加。但是，迄今为止，对于乙酸盐还是胆碱示踪剂是优选的，尚无最终结论。在本综述中，我们基于最近十年的文献，概述了胆碱和醋酸酯PET在PCA的原发性和复发性疾病及淋巴结分期中的性能。尽管主要使用胆碱而非乙酸盐，但两种示踪剂在已发表的研究中均以相似的方式进行。胆碱和乙酸盐对于原发性肿瘤的分期没有足够的诊断准确性，这是因为可检测到的最小肿瘤大小为5 mm，并且无法将PCA与良性前列腺增生，慢性前列腺炎和高度上皮内瘤变区分开。关于淋巴结分期，胆碱示踪剂已显示出高特异性。不幸的是，灵敏度仅为中等。对于分期复发的疾病，敏感性取决于血清PSA的水平（PSA应> 2 ng / ml）。这适用于胆碱和乙酸盐。然而，尽管有这些限制，但是通过改变治疗计划，仍有大量复发性疾病患者可以从PET成像中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号